Systemic treatments for noninfectious vitreous inflammation

Area of Science:

• Ophthalmology
• Rheumatology
• Immunology

Background:

• Vitritis, or inflammation of the vitreous humor, can stem from diverse causes, including infections, rheumatologic conditions, and autoimmune diseases.
• This condition poses a significant threat to vision and can lead to severe complications.
• Effective management of vitritis is often complex, necessitating a range of therapeutic strategies.

Purpose of the Study:

• To provide an updated overview of systemic treatment options for vitritis.
• To discuss recent therapeutic advancements and discoveries in the past year.
• To review the mechanisms of action, dosages, indications, adverse effects, and treatment courses for various drug classes.

Main Methods:

• Review of current literature and recent findings on systemic therapies for vitritis.
• Categorization of treatments including corticosteroids, antimetabolites, alkylating agents, T-cell inhibitors/calcineurin inhibitors, and biologic agents.
• Analysis of updated information on drug efficacy, safety, and clinical application.

Main Results:

• Significant progress has been made in understanding the indications and efficacy of existing and novel therapies for vitritis over the past year.
• Detailed insights into mechanisms of action, clinical dosages, specific treated conditions, adverse effects, and treatment protocols are presented for each therapeutic class.
• The review synthesizes the latest evidence on managing this challenging ocular inflammatory condition.

Conclusions:

• Systemic therapies offer multiple treatment avenues for vitritis, with ongoing research continually refining their application.
• Understanding the latest advancements in drug therapy is crucial for optimizing patient outcomes and mitigating vision loss.
• This review serves as a valuable resource for clinicians managing patients with vitritis, incorporating the most recent therapeutic developments.